A first-in-class oral CYP17 inhibitor proposed initially for use in combination with prednisone to treat metastatic castration-resistant prostate cancer (CRPC) in patients previously treated with a docetaxel chemotherapy.
If you have a Hayes login, click here to view the full report on the Knowledge Center.